Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | PALB2 dec exp |
Therapy | Evofosfamide |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | Evofosfamide | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by Evofosfamide (TH-302) in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 |
PubMed Id | Reference Title | Details |
---|---|---|
(25193512) | Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer. | Full reference... |